(b) for how many years phased manufac. turing programme lor such drugs lias been approved and from what stage in case of each drugs;

(c) whether foreign exchanges outgo visa-vis the import of drug was kept in view; and

(d) if so, what is the position of Rifampicin and Pyrazinamide and what is the difference in import content between import of intermediates and import of drug?

THE MINISTER OF INDUSTRY (SHRl J. VENGAL RAO): (a) and (b) In the case of the following drugs where technology for basic production is not readily available a phased indigenisation programme has been fixed:—

SI No	Name of drug	Name of the intermediate allowed far import for the first two years
1.		
2.	Sulphadiazine	. 2-Aminopyrim.idine
3	Sulphadoxine	. 2-MethyIthio-4-amino-r5,6-dimethoxy-pyrimidine
4.	Cimetidine	4-Methyl-5-Hydroxy Imidazole
5.		
6,	Ethambutol	. From imported DL-2 Aminobutanol till indigenous capacity is established.
7.	Thicridozlne	. 2-(1-methyl piperidyl-2)-efhan-l-01.
X.		
9.	Cf azolin .	. Import of 7-ACA may be allowed till it indigeneusly available
10.	Diphcnyl Hydantion	. Name of intermediate not specified
11	Melphalan .	. Name of intermediate not specified.

(c) Yes, Sir.

(d) Rifampicin and Pyrazinamide are being produced from intermediate stages. CIF prices of intermediates and bulk drugs are not monitored by this Ministry.

Marketing of products of small scale units units

3734. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 712 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the names, of the products of small scale units being marketed by organised sector units known to his Ministry;

(b) what are the reasons for which even after a lapse of one year the prices of such products have been fixed;

(c) what is the price overcharged by each company and when such an amount would be recovered; and

(d) for what purposes such recoveries would be utilised?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) A number of SSI units are marketing their products through Organised Sector Units. The required details arc therefore not readily available. Time and efforts required for collection.

of the same will not be commensurate with the results likely to be achieved.

(b) Whenever an instance of an SSI unit marketing its product through an Organised Sector Unit comes to the notice of the Government, both the units are directed to seek price approval for concerned formulations wherever necessary. Price fixation of formulation is a continuous process.

(c) and (d) Do not arise in view of reply to (b) above.

Increase in thc prices of single ingredient formulations

3735. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) what is the increase in the prices of single ingredient formulations sold under generic name by the ten leading companies engaged in the production of drugs;

(b) what were their prices under DPCO, 1979 and what are their prices now:

(c) what are the various packs of Rifa-mpicin, Fyrazinamide and their combinations for which prices have been fixed under DPCO, 1987 and what is the price fixed for each pack; and

(d) whether any instance of over-charging of price has come to Government's notice?

THE MINISTER OF INDUSTRY (SHRI /. VENGAL RAO): (a) and (b) The required details in the question are quite voluminous. The time and effort required for colleudon of these will not be commensurate with the results likely to be achieved.

(c) The required details to the extent available are given in the enclosed Statement. *(See* Appendix CXLVII, Annexure No. 131].

(d) Whenevcr such instance come to th^ notice of the Government, appropriate action is taken as per the provisions of DPCO, 1987.

Production and imports of formulation

3736. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1553 given in the Rajya Sabha on the 8th August, 1988 and state:

(a) what is the sales turnover according to ORG of Saridon, Neosporin, Sugranil, Zolandin, Actifed, Nebasulf Dilosyn Fluocort and Benadryl;

(b) what are the bulk drugs on which these formulations are based and whether they are price controlled or not;

(c) what was their production and im ports durins the last three years, yearwise; and

(d) how many companies are licenced and engaged in the production of each of these drugs?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Sales turnover is not monitored.

(b) The required details to the extent available are given in the enclosed Statement. *(See* below) All bulk drugs referred to in the question are price-decontrolled except Paracetamol.

(c) and (d) The required details to the extent available are given at annexure-IL (See Appendix CXLVIT, Annexure No. 132)